Improving Control of Gene Therapy-Based Neurotrophin Delivery for Inner Ear Applications.

St Peter, Madeleine; Brough, Douglas E; Lawrence, Anna; Nelson-Brantley, Jennifer; Huang, Peixin; Harre, Jennifer; Warnecke, Athanasia; Staecker, Hinrich

St Peter, Madeleine; Brough, Douglas E; Lawrence, Anna; Nelson-Brantley, Jennifer; Huang, Peixin; Harre, Jennifer; Warnecke, Athanasia; Staecker, Hinrich.

Affiliation

St Peter M; University of Kansas School of Medicine, Kansas City, KS, United States.
Brough DE; Precigen Inc., Gaithersburg, MD, United States.
Lawrence A; Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States.
Nelson-Brantley J; University of Kansas School of Medicine, Kansas City, KS, United States.
Huang P; Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States.
Harre J; Department of Otolaryngology, Hannover Medical School, Hannover, Germany.
Warnecke A; Department of Otolaryngology, Hannover Medical School, Hannover, Germany.
Staecker H; Department of Otolaryngology, University of Kansas School of Medicine, Kansas City, KS, United States.

Front Bioeng Biotechnol ; 10: 892969, 2022.

Article de En | MEDLINE | ID: mdl-35721868

Mots clés

brain-derived neurotrophic factor; herpes latency promoter; neurotrophin 3; ototoxicity; spiral ganglion neurons

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Bioeng Biotechnol Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google